<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00338455</url>
  </required_header>
  <id_info>
    <org_study_id>CR003649</org_study_id>
    <secondary_id>A051</secondary_id>
    <secondary_id>TMAC</secondary_id>
    <nct_id>NCT00338455</nct_id>
  </id_info>
  <brief_title>Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC</brief_title>
  <official_title>Investigation of the Use of Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scios, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scios, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study in United Network for Organ Sharing (UNOS) Status 1B (or country
      equivalent) cardiac transplant candidates are to assess the safety and efficacy of Natrecor
      (nesiritide). The study will evaluate the drug's ability to prevent clinical worsening when
      administered as a 28-day continuous intravenous infusion in patients receiving standard care
      and continuous intravenous infusion of dobutamine or milrinone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endogenous B-type natruretic peptide (BNP) concentrations correlate with heart failure (HF)
      severity and are significantly elevated in severe end-stage HF patients. However, normal
      biologic compensatory responsiveness to BNP is attenuated in patients with severe HF.
      Patients who are UNOS 1B cardiac transplant candidates have relatively few options for
      therapy, despite the fact that they constitute a very ill patient population. These options
      include getting a transplant, if one is available, receiving intravenous inotropes and/or
      vasodilators, or being implanted with a circulatory support device (e.g. Left Ventricular
      Assist Device). Natrecor (Nesiritide) is a human recombinant form of BNP approved for use in
      the treatment of acute decompensated HF. Limited information is available from controlled
      clinical trials on the effects of Natreor (nesiritide) infusion for longer than 72 hours.
      However, based on reports in the literature, Natrecor (nesiritide) has been used by
      independent investigators for much longer durations in end-stage HF patients, including UNOS
      Status 1B cardiac transplant candidates, who are refractory to standard care. In these
      patients, Natrecor (nesiritide) has been safely administered by continuous infusion for more
      than 2 and up to 210 days. These experiences showed that continuous Natrecor (nesiritide)
      infusion was well tolerated, uniformly improved hemodynamics (circulation of the blood and
      the forces involved), maintained stable renal (kidney) function, and reduced the need for
      ventricular assist devices during the prolonged wait for heart transplant. In controlled
      clinical trials reported in literature, Natrecor (nesiritide) was given concomitantly with
      several other standard HF therapeutic agents, such as diuretics, angiotensin-converting
      enzyme (ACE) inhibitors, beta-blockers, dopamine, dobutamine, anticoagulants, digoxin, and
      oral nitrates. Concomitant dosing was well tolerated, and no drug interactions were observed.
      No randomized controlled trial has been conducted to evaluate the safety of combination
      nesiritide and milrinone therapy. Several investigations were undertaken because of concerns
      over the potential additive hypotensive (lowering blood pressure) effect that these two
      agents may exert when administered concurrently. The study investigators reported that
      concurrent dosing of milrinone and nesiritide appeared to be safe and beneficial, without
      evidence of an additive hypotensive (lowering blood pressure) effect. The TMAC trial will
      investigate the safety and efficacy of Natrecor (nesiritide), compared with placebo, when
      added to standard care in the management of end-stage refractory HF.This prospective,
      randomized(patients are assigned different treatments based on chance), parallel,
      multicenter, double-blind (neither the doctor nor the patient knows whether the patient is
      being administered a placebo or the test drug), placebo-controlled study will be conducted
      with UNOS Status 1B (or equivalent) cardiac transplant candidates who are receiving standard
      care and continuous IV infusion of dobutamine or milrinone while awaiting heart
      transplantation. Approximately 120 patients will participate in this study. Enrolled patients
      will be randomized 1:1 to receive Natrecor (nesiritide) by continuous infusion in addition to
      standard care and one inotrope (drugs such as dobutamine or milrinone used to increase the
      heart rate and improve the force of cardiac contraction), or to receive placebo by continuous
      infusion in addition to standard care and one inotrope (dobutamine or milrinone). Patients
      will be managed as inpatients or outpatients, according to the guidelines in this protocol
      and study center practices. All patients will continue to receive their usual long-term
      cardiac medications (excluding commercial nesiritide). Study drug dose adjustments may be
      made according to the guidelines in this protocol and the investigator's clinical judgment,
      and in accordance with the dosing guidelines.Study drug will be administered as a continuous
      intravenous infusion under the control of a programmable ambulatory infusion pump for the
      28-day treatment period. Patients will be hospitalized for study drug initiation and
      titration to ensure safety, observe tolerability, and achieve the recommended study drug
      dose. Day 0 (Screening) will entail completing required procedures and randomization.
      Baseline and screening procedures may occur on the same day. A window of up to 7 days will be
      permitted between Day 0 (Screening) and Day 1 (Baseline) visits if circumstances delay
      initiation of study drug dosing. The following day, Day 1 (Baseline), continuous infusion of
      study drug will begin. Patients will be hospitalized for a minimum of 3 days after starting
      the study drug for titration and dose optimization. A dose optimization period of up to 5
      days will be permitted. Patients will be eligible for discharge following completion of the
      study procedures on the 4th dosing day (Day 4). Patients will return to the clinic for weekly
      visits (Â± 2 days) through Day 28 (Termination of Treatment) and again at Day 35 for a 7-day
      post dosing safety visit. On the Day 28 visit (Termination of Treatment), Patients may be
      hospitalized for up to 24 hours at the investigator's discretion to undergo end of treatment
      study procedures. This study includes two substudies: the Pulmonary Function Testing Substudy
      and the Glomerular Filtration Rate Substudy. All TMAC Patients will be asked to participate
      in these substudies. Participation is optional and does not affect enrollment or
      participation in TMAC. The Study Hypothesis is that continuous administration of Natrecor
      (nesiritide) over 28 days when added to standard care (including inotropes) is safe and
      provides a clinical benefit when compared to placebo added to standard care (including
      inotropes) therapy. Study drug will be administered continuously as a fixed-rate infusion for
      28 days without a bolus dose. Natrecor (nesiritide) dosing will begin at 0.005 mcg/kg/min and
      may be titrated to a maximum dose of 0.015 mcg/kg/min.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    DSMC acknowledged no safety concerns with the trial, recommending that the trial be terminated
    due to slow enrollment
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Days Alive Without Renal, Hemodynamic, or Electrical Clinical Worsening Through Day 28 (Termination of Treatment)</measure>
    <time_frame>28 days</time_frame>
    <description>Number of calendar days alive without renal, hemodynamic, or electrical clinical worsening through Day 28 (termination of treatment or early discontinuation of treatment, whichever occurred first). The endpoint was not normalized for time on study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Pulmonary Capillary Wedge Pressure (PCWP)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>Day 30 and Months 2 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Pulmonary Artery Pressure (PAP): Systolic, Diastolic, and Mean</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Congestive Heart Failure</condition>
  <condition>Cardiac Transplantation</condition>
  <condition>Renal Insufficiency</condition>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Natrecor (nesiritide)+Standard Care+dobutamine or milrinone 28-day continuous infusion no bolus 3-hour 0.005 mcg/kg/min may be titrated to 0.015 mcg/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo+Standard Care+dobutamine or milrinone 28-day continuous infusion no bolus 3-hour 0.005 mcg/kg/min may be titrated to 0.015 mcg/kg/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natrecor (nesiritide)+Standard Care+dobutamine or milrinone</intervention_name>
    <description>3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo+Standard Care+dobutamine or milrinone</intervention_name>
    <description>28-day continuous infusion, no bolus</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet the criteria for a United Network for Organ Sharing (UNOS) Status 1B heart
             transplant candidate, or, if outside the US, have comparable status

          -  must also be a primary transplant candidate waiting to receive a single cardiac
             allograft

          -  must be receiving continuous intravenous infusion of dobutamine or milrinone through a
             double-lumen central catheter or a double-lumen percutaneously inserted central
             catheter for at least 3 consecutive days before randomization

          -  must be willing and able to participate in the study assessments and follow up
             procedures

          -  male and female subjects of childbearing potential agree to use two highly effective
             methods of birth control for the duration of the study.

        Exclusion Criteria:

          -  Not have systolic blood pressure (SBP) consistently &lt; 80 mm Hg, or have clinically
             significant orthostatic hypotension

          -  not weigh &gt; 130 kg

          -  not have a ventricular assist device (VAD), or anticipate the need for a VAD, during
             the 28-day study drug treatment period

          -  not have received placement of an internal cardiac defibrillator (ICD) or external
             cardiac defibrillator (ECD) within 72 hours before randomization

          -  not require chronic hemodialysis or peritoneal dialysis to treat renal failure, or had
             acute dialysis or ultrafiltration within 7 days before randomization

          -  not have received antibiotic treatment within 7 days before randomization-antibiotics
             are permissible for any prophylactic use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scios, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Scios, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2006</study_first_submitted>
  <study_first_submitted_qc>June 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2006</study_first_posted>
  <results_first_submitted>October 22, 2008</results_first_submitted>
  <results_first_submitted_qc>December 4, 2008</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 5, 2008</results_first_posted>
  <last_update_submitted>November 20, 2014</last_update_submitted>
  <last_update_submitted_qc>November 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Congestive heart failure</keyword>
  <keyword>cardiac transplantation</keyword>
  <keyword>renal insufficiency</keyword>
  <keyword>renal failure</keyword>
  <keyword>dialysis</keyword>
  <keyword>ultrafiltration</keyword>
  <keyword>vasodilator</keyword>
  <keyword>Natrecor (nesiritide)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dobutamine</mesh_term>
    <mesh_term>Milrinone</mesh_term>
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of the 16 participants randomized in the study, 1 participant randomized to receive nesiritide was not administered study drug due to investigator decision.Summaries of baseline characteristics are based on the 16 participants who were randomized in the study. Safety and efficacy analyses were based on the 15 participantswho received study drug.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Natrecor (Nesiritide)+Standard Care+Dobutamine or Milrinone</title>
          <description>Nesiritide - 28-day continuous infusion, no bolus; 3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min.</description>
        </group>
        <group group_id="P2">
          <title>Placebo + Standard Care + Dobutamine or Milrinone</title>
          <description>Placebo - 28-day continuous infusion, no bolus; 3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Administered Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Natrecor (Nesiritide)+Standard Care+Dobutamine or Milrinone</title>
          <description>Nesiritide - 28-day continuous infusion, no bolus; 3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min.</description>
        </group>
        <group group_id="B2">
          <title>Placebo + Standard Care + Dobutamine or Milrinone</title>
          <description>Placebo - 28-day continuous infusion, no bolus; 3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.0" spread="9.80"/>
                    <measurement group_id="B2" value="54.6" spread="4.65"/>
                    <measurement group_id="B3" value="53.1" spread="7.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glomerular Filtration Rate (GFR)</title>
          <description>Estimate of the GFR using serum creatinine and demographic factors.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>GFR &lt; 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GFR &gt; = 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.4" spread="5.53"/>
                    <measurement group_id="B2" value="31.7" spread="5.79"/>
                    <measurement group_id="B3" value="30.5" spread="5.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Days Alive Without Renal, Hemodynamic, or Electrical Clinical Worsening Through Day 28 (Termination of Treatment)</title>
        <description>Number of calendar days alive without renal, hemodynamic, or electrical clinical worsening through Day 28 (termination of treatment or early discontinuation of treatment, whichever occurred first). The endpoint was not normalized for time on study.</description>
        <time_frame>28 days</time_frame>
        <population>Early termination of the study due to enrollment difficulties; efficacy not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Natrecor (Nesiritide)+Standard Care+Dobutamine or Milrinone</title>
            <description>Nesiritide - 28-day continuous infusion, no bolus; 3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Standard Care + Dobutamine or Milrinone</title>
            <description>Placebo - 28-day continuous infusion, no bolus; 3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Alive Without Renal, Hemodynamic, or Electrical Clinical Worsening Through Day 28 (Termination of Treatment)</title>
          <description>Number of calendar days alive without renal, hemodynamic, or electrical clinical worsening through Day 28 (termination of treatment or early discontinuation of treatment, whichever occurred first). The endpoint was not normalized for time on study.</description>
          <population>Early termination of the study due to enrollment difficulties; efficacy not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Pulmonary Capillary Wedge Pressure (PCWP)</title>
        <time_frame>28 days</time_frame>
        <population>Early termination of the study due to enrollment difficulties; efficacy not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Natrecor (Nesiritide)+Standard Care+Dobutamine or Milrinone</title>
            <description>Nesiritide - 28-day continuous infusion, no bolus; 3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Standard Care + Dobutamine or Milrinone</title>
            <description>Placebo - 28-day continuous infusion, no bolus; 3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Pulmonary Capillary Wedge Pressure (PCWP)</title>
          <population>Early termination of the study due to enrollment difficulties; efficacy not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <time_frame>Day 30 and Months 2 and 6</time_frame>
        <population>Early termination of the study due to enrollment difficulties; efficacy not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Natrecor (Nesiritide)+Standard Care+Dobutamine or Milrinone</title>
            <description>Nesiritide - 28-day continuous infusion, no bolus; 3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Standard Care + Dobutamine or Milrinone</title>
            <description>Placebo - 28-day continuous infusion, no bolus; 3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min.</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <population>Early termination of the study due to enrollment difficulties; efficacy not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Pulmonary Artery Pressure (PAP): Systolic, Diastolic, and Mean</title>
        <time_frame>28 days</time_frame>
        <population>Early termination of the study due to enrollment difficulties; efficacy not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Natrecor (Nesiritide)+Standard Care+Dobutamine or Milrinone</title>
            <description>Nesiritide - 28-day continuous infusion, no bolus; 3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Standard Care + Dobutamine or Milrinone</title>
            <description>Placebo - 28-day continuous infusion, no bolus; 3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Pulmonary Artery Pressure (PAP): Systolic, Diastolic, and Mean</title>
          <population>Early termination of the study due to enrollment difficulties; efficacy not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Safety evaluations were to be performed on treatment and at Months 2 and 6.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Natrecor (Nesiritide)+Standard Care+Dobutamine or Milrinone</title>
          <description>Nesiritide - 28-day continuous infusion, no bolus; 3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min.</description>
        </group>
        <group group_id="E2">
          <title>Placebo + Standard Care + Dobutamine or Milrinone</title>
          <description>Placebo - 28-day continuous infusion, no bolus; 3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>catheter related complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>catheter site discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>clostridium colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>naospharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>gallop rythm present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>gout</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>hypervolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>hypochloraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>rales</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>jugular vein distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination of the study due to enrollment difficulties (change in standard of care for patient population as well as changing organ allocation rules by United Network for Organ Sharing); efficacy not analyzed due to limited sample size (n=16).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sr. Director Clinical Leader</name_or_title>
      <organization>Scios R&amp;D, Inc.</organization>
      <phone>650 564-5084</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

